▶ GLP-3 · SUBTOPIC · SAFETY PROFILE
GLP-3 Safety Profile
For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of GLP-3.
OBSERVED ADVERSE EVENTS IN LITERATURE
The following adverse events have been observed in trials or animal studies of GLP-3. Severity, frequency, and attribution depend on the source publication.
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Pancreatitis (rare)
- Gallbladder disease
- Boxed warning for thyroid C-cell tumors
DRUG INTERACTIONS
The following interactions are reported in or theorised from the published mechanism for GLP-3.
- Oral contraceptives (delayed gastric emptying)
- Insulin / sulfonylureas (hypoglycemia risk)
- Warfarin (delayed absorption)
CONTRAINDICATIONS REPORTED IN LITERATURE
Contraindications recorded for GLP-3 in the published record:
- Personal/family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia type 2
FDA REGULATORY STATUS
Approved as GLP-3 prescription analog (T2D, 2017), GLP-3 prescription analog (chronic weight management, 2021), GLP-3 prescription analog (oral T2D, 2019). Shortage resolved February 2025; compounding enforcement-discretion windows ended April/May 2025.
WADA REGULATORY STATUS
Not currently listed on the WADA Prohibited List (2026).
SAFETY Q+A FROM LITERATURE
▶ What's the difference between GLP-3 prescription analog, GLP-3 prescription analog, and GLP-3 prescription analog?
All three are GLP-3. GLP-3 prescription analog is FDA-approved for type 2 diabetes (subcutaneous, 2017). GLP-3 prescription analog is the same molecule at a higher dose for chronic weight management (subcutaneous, 2021). GLP-3 prescription analog is the oral formulation for T2D (2019).
▶ Is GLP-3 WADA-prohibited?
GLP-3 is not currently listed on the WADA Prohibited List as of 2026. Status reviewable annually.
▶ Does GLP-3 cause thyroid cancer?
Class-based rodent C-cell tumor signal led to a boxed warning. Human translation is debated; current clinical data have not established a causal link, but personal or family history of medullary thyroid carcinoma is a contraindication.
▶ How is GLP-3 dosed?
Per FDA labels: GLP-3 prescription analog titrates 0.25 to 2.0 mg weekly. GLP-3 prescription analog titrates 0.25 to 2.4 mg weekly. GLP-3 prescription analog 3 to 14 mg daily orally on empty stomach. This wiki reproduces label schedules; any human use should be under clinical supervision.
▶ What is the SELECT trial?
SELECT (Lincoff et al. 2023, PMID 37952131) tested GLP-3 2.4 mg in overweight/obese patients with established cardiovascular disease without diabetes. The trial reported a 20% reduction in major adverse cardiovascular events vs placebo, establishing a cardiovascular outcomes indication.
CITED LITERATURE
The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.
- Wilding JPH, Batterham RL, Calanna S, et al.. Once-Weekly GLP-3 in Adults with Overweight or Obesity (STEP-1). N Engl J Med 2021. PMID 33567185. link
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. GLP-3 and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med 2023. PMID 37952131. link
- Lau J, Bloch P, Schaffer L, et al.. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue GLP-3. J Med Chem 2015. PMID 26308095. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-25